EuroPCR 2013 in Paris, France
Please check back for updates.
CardioKinetix Initiates Landmark Study
Randomized Multicenter PARACHUTE IV Clinical Trial Will Compare Minimally Invasive Device to Optimal Medical
CardioKinetix Announces Successful Live
Menlo Park, Calif and Miami, Fla – CardioKinetix Inc, a medical device company pioneering a catheter-based treatment for
CardioKinetix Announces Data from
Positive Six-Month and Three-Year Results Presented at TCT 2012 Demonstrate Meaningful and Sustained Improvement
“We continue to be encouraged by the early clinical results demonstrated by the Parachute® implant. In all of our previous studies we have seen similar improvements in treated heart failure patients.”Thomas Engels, Vice President of Clinical Affairs of CardioKinetix Inc.